{"id":"us-sourced-yervoy","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Pruritus"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"5-10%","effect":"Decreased appetite"},{"rate":"5-10%","effect":"Weight loss"},{"rate":"5-10%","effect":"Arthralgia"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL2109615","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, YERVOY prevents the PD-1 ligands (PD-L1 and PD-L2) from interacting with PD-1, thereby releasing the brakes on the immune system and allowing it to attack cancer cells. This mechanism is thought to be responsible for the anti-tumor activity of YERVOY.","oneSentence":"YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:17.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Adenocarcinoma of the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors"},{"name":"Colorectal cancer"},{"name":"Renal cell carcinoma"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Hepatocellular carcinoma"},{"name":"Non-small cell lung cancer"},{"name":"Urothelial carcinoma"}]},"trialDetails":[{"nctId":"NCT07176650","phase":"PHASE1","title":"Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-11-25","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":246},{"nctId":"NCT06841185","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":656},{"nctId":"NCT06159101","phase":"PHASE1","title":"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-11-28","conditions":"Healthy Male Volunteers","enrollment":304}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"US-sourced YERVOY®","genericName":"US-sourced YERVOY®","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Metastatic melanoma, Adenocarcinoma of the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, Colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}